Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

Gilead Sciences (GILD) closed at $72.09 in the latest trading session, marking a -1.08% move from the prior day.

Gilead Sciences (GILD) Stock Moves -0.04%: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.58, moving -0.04% from the previous trading session.

Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know

Gilead Sciences (GILD) reachead $73.41 at the closing of the latest trading day, reflecting a +0.2% change compared to its last close.

Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know

Gilead Sciences (GILD) closed the most recent trading day at $75.94, moving +1.15% from the previous trading session.

Why Gilead Sciences (GILD) Outpaced the Stock Market Today

In the most recent trading session, Gilead Sciences (GILD) closed at $73.66, indicating a +1.42% shift from the previous trading day.

Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II

Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today

In the latest trading session, Gilead Sciences (GILD) closed at $72.31, marking a +0.29% move from the previous day.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Zacks Analyst Blog Highlights Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo

Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Merck, ServiceNow & Blackstone

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX).

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

Smart Beta ETF report for VALQ

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.

Yashwardhan Jain headshot

Where Are Biotech ETFs Headed After Q4 Earnings?

Look into how Biotech ETFs performed after Q4 earnings.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline

Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.

Company News for Feb 13, 2024

Companies In The Article Are: FANG, JOBY,C, CBAY and GILD

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO

Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.